What does a pseudo‑Pelger‑Huët anomaly indicate and how should it be evaluated and managed?

Pseudo-Pelger-Huët Anomaly

Pseudo-Pelger-Huët anomaly is a morphologic finding of hypolobated granulocyte nuclei that most importantly signals myelodysplastic syndrome (MDS) or acute myeloid leukemia, but can also represent reversible medication effects, severe infections, or other reactive conditions—requiring immediate bone marrow evaluation with cytogenetics to distinguish malignant from benign causes. 1, 2

What It Indicates

Pseudo-Pelger-Huët anomaly represents granulocyte nuclear hypolobation (abnormally decreased nuclear segmentation) visible on peripheral blood smear. This is a form of myeloid dysplasia that appears as:

• Neutrophils with bilobed or monolobular nuclei instead of the normal 3-5 lobes
• Excessive chromatin clumping
• May be accompanied by cytoplasmic hypogranulation/degranulation 1, 2

Primary Concern: Myelodysplastic Syndrome

The European LeukemiaNet guidelines explicitly list pseudo-Pelger-Huët as a characteristic feature of myeloid dysplasia in MDS, appearing in both peripheral blood and bone marrow 1. The 2021 ESMO guidelines similarly identify "pseudo Pelger-Huet cells" as a key dysplastic feature in granulocytes 2.

Alternative Causes (Reversible)

However, pseudo-Pelger-Huët can also represent iatrogenic or reactive changes:

• Medications: Immunosuppressive drugs (particularly in transplant recipients), chemotherapy agents 3, 4
• Severe infections: Human granulocytic anaplasmosis and other severe bacterial infections 5
• Other conditions: Radiation exposure, inflammatory states 6, 7

Critical distinction: Medication-induced pseudo-Pelger-Huët typically shows higher percentages of affected cells (mean 47.4% vs 12.3% in MDS) and resolves with medication adjustment, whereas MDS-related changes persist and are accompanied by other bone marrow abnormalities 3.

Evaluation Algorithm

Step 1: Mandatory Initial Workup

When pseudo-Pelger-Huët is identified, the following are mandatory 1:

1. Complete medication review: Immunosuppressants (tacrolimus, mycophenolate), chemotherapy, other myelosuppressive agents
2. Infection screening: Particularly tick-borne illnesses if clinically appropriate
3. Peripheral blood smear review:
   • Count at least 200 cells
   • Quantify percentage of pseudo-Pelger-Huët cells
   • Look for other dysplastic features (hypogranulation, giant platelets, basophilic stippling)
   • Enumerate blasts

Step 2: Bone Marrow Examination (Mandatory Unless Clearly Iatrogenic)

Proceed immediately to bone marrow evaluation unless there is clear medication cause with high percentage of affected cells and no cytopenias 1:

Bone marrow aspirate (mandatory):

• Evaluate dysplasia in all three lineages (count ≥500 cells including ≥100 erythroblasts and ≥30 megakaryocytes)
• Enumerate blasts
• Assess for ring sideroblasts (Prussian blue staining)
• Dysplasia is significant if >10% of cells in a lineage are affected 1

Bone marrow biopsy (mandatory):

• Assess cellularity and fibrosis
• Evaluate megakaryocytic dysplasia (often better seen on biopsy than aspirate) 1, 2

Cytogenetic analysis (mandatory):

• Analyze ≥20 metaphases when possible
• Look for MDS-associated abnormalities: del(5q), monosomy 7/del(7q), trisomy 8, del(20q) 1
• If metaphases fail, use FISH for targeted abnormalities 1, 2

Flow cytometry immunophenotyping (recommended):

• Detect abnormalities in myeloid maturation patterns 1

Molecular testing (suggested):

• Screen for recurrent mutations (SF3B1, TET2, ASXL1, TP53) 1

Step 3: Diagnostic Decision Tree

If bone marrow shows ≥2 of the following → Diagnose MDS 3:

• Hypercellularity
• Morphologic dysplasia in multiple lineages
• Clonal cytogenetic abnormality
• Increased blasts

If bone marrow is normal AND medication cause identified:

• Adjust or discontinue offending medication
• Repeat peripheral smear in 2-4 weeks to confirm resolution 3, 4
• If persists despite medication change → reconsider MDS

If isolated pseudo-Pelger-Huët with normal bone marrow and no clear cause:

• Observe with repeat bone marrow in 6 months 1
• These patients typically have mild cytopenia only and unlikely rapid progression

Common Pitfalls

1. Mistaking early neutrophils for pseudo-Pelger-Huët cells: True pseudo-Pelger-Huët shows hypercondensed chromatin, not immature chromatin pattern 4

2. Assuming all pseudo-Pelger-Huët indicates MDS: Medication-induced changes are reversible and should not trigger unnecessary aggressive workups if clearly iatrogenic with very high percentages of affected cells 3

3. Delaying bone marrow evaluation: When MDS is suspected (cytopenias, lower percentage of pseudo-Pelger-Huët cells, other dysplastic features), bone marrow examination should not be delayed 1

4. Inadequate cell counting: Counting <200 cells on peripheral smear or <500 cells on bone marrow aspirate reduces diagnostic accuracy 1

Management Implications

The presence of pseudo-Pelger-Huët fundamentally changes management based on the underlying cause:

• If MDS confirmed: Risk stratification using IPSS-R score (which includes cytogenetics), then treatment based on risk category and transfusion dependence
• If medication-induced: Medication adjustment with hematologic monitoring
• If infection-related: Treat underlying infection (e.g., doxycycline for anaplasmosis) with expected resolution 5

The key is that pseudo-Pelger-Huët cannot be dismissed as benign without proper evaluation, as it may represent the first sign of a life-threatening hematologic malignancy requiring disease-modifying therapy.